Effect of Osteoarthritis Drugs on inflammatory markers and its relation with Clinical Outcome
Not Applicable
- Conditions
- Health Condition 1: M179- Osteoarthritis of knee, unspecified
- Registration Number
- CTRI/2023/04/051950
- Lead Sponsor
- Vardhman Mahavir Medical College and Safdarjung Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Clinically and radiologically confirmed diagnosed cases of osteoarthritis as defined
by ACR criteria
Exclusion Criteria
1. Coexisting acute illness.
2. Person should not have taken anti-inflammatory drugs for more than 7 days in the
past 4 weeks or on any day during the period of 5 days just before starting the trial.
3. On corticosteroids or immunosuppressive drugs.
4. Any acute injury or recent surgery (past 3 month).
5. History of intra-articular injection in the knee in past 6 months.
6. Pregnancy and lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method primary: <br/ ><br>To study the effect of DMOAD (Diacerein) in OA knee patient by assessing the pre treatment and post treatment change in: <br/ ><br>� levels of inflammatory markers (IL-1β, IL-6, TNF-α) <br/ ><br>� KOOS and VAS score <br/ ><br>� Performance based test (30sec chair stand test, 40m fast pace walk test and stair <br/ ><br>climb test) <br/ ><br>2. Correlation of change in clinical outcomes and change in inflammatory markers. <br/ ><br>Timepoint: Follow up every 3rd week for 6 weeks
- Secondary Outcome Measures
Name Time Method Secondary <br/ ><br>1.Observation of adverse event of drug. <br/ ><br>2.Intolerance to disease modifying osteoarthritis drugTimepoint: Follow up every 3rd week for 6 weeks